N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
“The label change implemented by FDA is reflective of both the extensive data on contrast agents and the well characterized and stable safety profile of DEFINITY, which has been used to perform more ...
October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...
Wilmington, DE -DuPont Pharmaceuticals announced today they have received FDA approval for their Definity? (Perflutren Lipid Microsphere) ultrasound contrast agent. Definity is used to improve the ...
BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
Please provide your email address to receive an email when new articles are posted on . Lantheus Medical Imaging Inc. announced that the FDA has approved a label update that removes the ...
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics ...
In a comparison of patient outcomes after two stress imaging approaches, stress real-time myocardial contrast echocardiography improved the detection of CAD during stress echocardiography over ...
Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. 3-6 A suboptimal image is one in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results